Compare · DGX vs UNH
DGX vs UNH
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and UnitedHealth Group Incorporated (UNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and UNH operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $365.02B, about 13.8x DGX ($26.40B).
- UNH has been more active in the news (12 items in the past 4 weeks vs 3 for DGX).
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- UnitedHealth Group Incorporated
- Price
- -
- -
- Market cap
- $26.40B
- $365.02B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 3
- 12
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest DGX
- SEC Form 8-K filed by Quest Diagnostics Incorporated
- SEC Form 4 filed by Director Wentworth Timothy C
- Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
- Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
- Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
- Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
- Apple Health app Users to be Able to Order Labs from Quest Diagnostics
- CEO and President Davis J. E. sold $2,427,200 worth of shares (10,000 units at $242.72) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 122,423 units (SEC Form 4)
- SVP & General Counsel Prevoznik Michael E exercised 22,677 shares at a strike of $112.17, sold $5,513,083 worth of shares (22,677 units at $243.11) as part of a pre-agreed trading plan and gifted 1,000 shares, decreasing direct ownership by 3% to 36,557 units (SEC Form 4)
- Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
Latest UNH
- SEC Form 8-K filed by UnitedHealth Group Incorporated
- UnitedHealth Group Reports Third Quarter 2026 Results
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated